Valuation: Rapport Therapeutics, Inc.

Market Cap 211.1Cr 182.92Cr 172.62Cr 156.61Cr 293.78Cr 20TCr 295.91Cr 2.06TCr 794.43Cr 10TCr 792.89Cr 775.41Cr 33TCr P/E 2026 *
-10.9x
P/E 2027 * -8.98x
Enterprise Value 178.19Cr 154.41Cr 145.71Cr 132.19Cr 247.98Cr 17TCr 249.78Cr 1.74TCr 670.58Cr 8.66TCr 669.28Cr 654.53Cr 28TCr EV / Sales 2026 *
89.1x
EV / Sales 2027 * -
Free-Float
96.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.87%
1 week-3.87%
Current month-9.60%
1 month-7.21%
3 months+14.58%
6 months+58.05%
Current year+45.02%
1 week 42.65
Extreme 42.65
45.42
1 month 42.65
Extreme 42.65
52.93
Current year 25.21
Extreme 25.21
52.93
1 year 23.75
Extreme 23.75
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 01/01/2023
Chief Executive Officer 48 01/02/2023
Director of Finance/CFO 58 01/11/2023
Director TitleAgeSince
Director/Board Member 61 23/08/2023
Director/Board Member 48 01/03/2023
Director/Board Member 54 01/02/2022
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26 Sell

Chief Executive Officer

-8,210 0.0171%
25/08/26 Sell

Executive/Senior Manager

-37,000 0.0774%
25/08/26 Sell

Chief Executive Officer

-18,921 0.0396%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%-3.87%+85.19% - 209.28Cr
+0.56%-4.71%-2.45%+9.18% 4.55TCr
+0.66%-2.34%+340.62%+530.14% 4.37TCr
+1.49%-0.78%+41.90%+24.75% 4.31TCr
+2.11%-1.24%+9.09%+78.25% 3.94TCr
+0.34%-4.03%+9.34%+38.90% 3.19TCr
+0.53%-2.08% - - 1.73TCr
+1.34%+0.70%+21.35%+112.62% 1.64TCr
+2.07%+0.78%+13.07%+30.91% 1.42TCr
-1.85%-5.33%+78.63%+31.45% 1.33TCr
Average +0.81%-2.65%+66.31%+107.03% 2.67TCr
Weighted average by Cap. +0.94%-2.84%+76.08%+127.96%

Financials

2026 *2027 *
Net sales 2Cr 1.73Cr 1.64Cr 1.48Cr 2.78Cr 191.69Cr 2.8Cr 20Cr 7.53Cr 97Cr 7.51Cr 7.35Cr 309.16Cr -
Net income -19Cr -17Cr -16Cr -14Cr -27Cr -1.86TCr -27Cr -189.58Cr -73Cr -943.89Cr -73Cr -71Cr -3TCr -25Cr -22Cr -21Cr -19Cr -35Cr -2.42TCr -35Cr -246.49Cr -95Cr -1.23TCr -95Cr -93Cr -3.9TCr
Net Debt -33Cr -29Cr -27Cr -24Cr -46Cr -3.15TCr -46Cr -321.4Cr -123.85Cr -1.6TCr -123.61Cr -120.88Cr -5.09TCr -48Cr -41Cr -39Cr -35Cr -66Cr -4.57TCr -67Cr -465.54Cr -179.39Cr -2.32TCr -179.04Cr -175.1Cr -7.37TCr
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
14/26/14 $44.00 +0.87% 1,96,924
11/26/11 $43.62 +0.37% 2,51,788
10/26/10 $43.46 -0.97% 3,19,264
09/26/09 $43.89 -4.78% 4,37,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
44.00USD
Average target price
62.05USD
Spread / Average Target
+41.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!